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Background: Chronic subdural hematoma (CSDH) is a very common clinical emergency
encountered in neurosurgery. While both general anesthesia (GA) and monitored
anesthesia care (MAC) can be used during CSDH surgery, MAC is the preferred choice
among surgeons. Further, while dexmedetomidine (DEX) is reportedly a safe and effective
agent for many diagnostic and therapeutic procedures, there have been no trials to
evaluate the safety and efficacy of DEX vs. sufentanil in CSDH surgery.
Objective: To evaluate the safety and efficacy of DEX vs. sufentanil in MAC during
burr-hole surgery for CSDH.
Methods: In all, 215 fifteen patients underwent burr-hole surgery for CSDH with MAC
and were divided into three groups: Group D1 (n = 67, DEX infusion at 0.5µg·kg−1
for 10min), Group D2 (n = 75, DEX infusion at 1 µg·kg−1 for 10min), and Group S
(n 73, sufentanil infusion 0.3 g kg−1= µ · for 10min). Ramsay sedation scale (RSS) of all
three groups was maintained at 3. Anesthesia onset time, total number of intraoperative
patient movements, hemodynamics, total cumulative dose of DEX, time to first dose and
amount of rescue midazolam or fentanyl, percentage of patients converted to alternative
sedative or anesthetic therapy, postoperative recovery time, adverse events, and patient
and surgeon satisfaction scores were recorded.
Results: The anesthesia onset time was significantly less in group D2 (17.36 ± 4.23 vs.
13.42± 2.12 vs. 15.98± 4.58min, respectively, for D1, D2, S; P < 0.001). More patients
in groups D1 and S required rescue midazolam to achieve RSS = 3 (74.63 vs. 42.67
vs. 71.23%, respectively, for D1, D2, S; P < 0.001). However, the total dose of rescue
midazolam was significantly higher in group D1 (2.8± 0.3 vs. 1.9± 0.3 vs. 2.0 ± 0.4mg,
respectively, for D1, D2, S; P < 0.001). The time to first dose of rescue midazolam was
significantly longer in group D2 (17.32 ± 4.47 vs. 23.56 ± 5.36 vs. 16.55 ± 4.91 min,
respectively, for D1, D2, S; P < 0.001). Significantly fewer patients in groups S and
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D2 required rescue fentanyl to relieve pain (62.69 vs. 21.33 vs. 27.40%, respectively, for
D1, D2, S; P < 0.001). Additionally, total dose of rescue fentanyl in group D1 group was
significantly higher (212.5 ± 43.6 vs. 107.2 ± 35.9 vs. 98.6 ± 32.2µg, respectively, for
D1, D2, S; P < 0.001). Total number of patient movements during the burr-hole surgery
was higher in groups D1 and S (47.76 vs. 20.00 vs. 47.95%, respectively, for D1, D2, S;
P < 0.001). Four patients in D1 and five in S converted to propofol. The time to recovery
for discharge from the PACU was significantly shorter in group D2 (16.24 ± 4.15 vs.
12.48 ± 3.29 vs. 15.91 ± 3.66min, respectively, for D1, D2, S; P < 0.001). Results
from the patient and surgeon satisfaction scores showed significant differences favoring
group D2 (P < 0.05). More patients in groups D1 and S showed higher levels of the
overall incidence of tachycardia and hypertension, and required higher doses of urapidil
and esmolol (P < 0.05). Six patients experienced respiratory depression in group S.
Conclusion: Compared with sufentanil, DEX infusion at 1µg·kg−1 was associated with
fewer intraoperative patient movements, fewer rescue interventions, faster postoperative
recovery, and better patient and surgeon satisfaction scores and could be safely and
effectively used for MAC during burr-hole surgery for CSDH.
Keywords: dexmedetomidine, sufentanil, monitored anesthesia care, chronic subdural hematoma, burr-hole
surgery
INTRODUCTION
Chronic subdural hematoma (CSDH) usually occurs in the
elderly with co-morbidities and multi-system disorders, and is
one of themost frequently encountered intracranial hemorrhages
in neurosurgery (Guzel et al., 2008; Ma and Fei, 2010). Burr-
hole surgery is commonly used for its initial treatment(Xu et al.,
2016). Previous studies have reported that general anesthesia
(GA), local anesthesia, or monitored anesthesia care (MAC)
alone could not provide adequate safety assurance for both
patients and surgeons. Nowadays, more and more medical
centers perform this procedure under local anesthesia associated
with MAC for its safety and efficacy during the surgery (Cenic
et al., 2005; Mekaj et al., 2008). Midazolam, propofol, opioids,
or a combination of these drugs are widely used during MAC;
however, each of these drugs has its limitations (Song et al., 2004;
Agostoni et al., 2011; Sato et al., 2016). While midazolam has no
analgesic property, its sedative pharmacological properties vary
with different patients and may be responsible for respiratory
depression. Propofol, which also lacks analgesic characteristics,
is a short-acting anesthetic agent. As per the FDA guidelines,
propofol administration should be closely monitored owing
to easily induced respiratory depression and hemodynamic
instability. Opioids such as fentanyl, sufentanil, and remifentanil
can provide excellent analgesia without sedation. The incidence
of adverse reactions, especially respiratory depression, will be
increased when used in higher doses or in combination with
other sedative agents. Most importantly, the American Society
of Anesthesiologist’s (ASA) Closed Claim Database revealed
that respiratory depression without close monitoring played an
important role in mishaps during MAC. (ASA Task Force on
Sedation Analgesia by Non Anesthesiologists, 2002) Because of
the unavoidable adverse effects of these drugs, the need for an
ideal sedative agent with limited adverse effects that can be used
safely and efficacy during MAC is urgent.
Dexmedetomidine (DEX), a highly selective agonist of the
α2 adrenergic receptor, has a more favorable pharmacokinetic
profile than clonidine: α2:α1 specificity ratio, 1600:1 vs. 200:1
and plasma half-life (T½), 2–2.5 h vs. 9–12 h. It also has many
clinical benefits, such as sedation without significant respiratory
depression, an analgesic-sparing effect, and a sympatholytic
effect that can attenuate the stress response to surgery (Geloen
et al., 2013). Previous studies have reported that DEX could be
used safely and effectively for many diagnostic and therapeutic
procedures (Jaakola et al., 1992; Demiraran et al., 2007). However,
according to an independent search of MEDLINE, PubMed,
EMBASE, Cochrane Central Register of Controlled Trials, and
Web of Science for English language articles between 2000 and
2015 and using the terms “dexmedetomidine,” “sufentanil,” and
“monitored anesthesia care,” there have been no trials that report
the use of DEX vs. sufentanil for surgical treatment of CSDH.
We conducted this retrospective trial to evaluate the safety and
efficacy of DEX vs. sufentanil for MAC during burr-hole surgery
for CSDH.
MATERIALS AND METHODS
Patients
The institutional review board of Liaocheng People’s Hospital
approved (No. 2016057) this retrospective trial, which was
registered at chictr.org (ChiCTR-IPR-16008494). Patients who
underwent burr-hole surgery for CSDH with MAC between
January 2014 and December 2015 and provided written informed
consent were enrolled in this study. The inclusion criteria were:
age between 45 and 65 years and ASA grade I to III. Exclusion
Frontiers in Pharmacology | www.frontiersin.org 2 November 2016 | Volume 7 | Article 410
Wang et al. Dexmedetomidine vs. Sufentanil for MAC
criteria included hypertension (diastolic blood pressure >
160mmHg); bradycardia (<50 bpm); ischemic heart disease
(<6 months); second- or third-degree heart block; long-term
abuse of or addiction to alcohol, tobacco, opioids, and sedative–
hypnotic drugs (>6 months); allergy to DEX and/or sufentanil;
neuropsychiatric diseases; operation time shorter than 30min;
emergent surgery.
Patients were divided into the following three groups: Group
D1 (n = 67, initial DEX infusion at 0.5 µg·kg−1 for 10 min,
then adjusted to 0.2–0.7µg·kg−1·h−1); Group D2 (n= 75, initial
DEX infusion at 1µg·kg−1 for 10 min, then adjusted to 0.2–
0.7µg·kg−1·h−1); andGroup S (n= 73, initial sufentanil infusion
at 0.3µg·kg−1 for 10 min, then adjusted to 0.1–0.3µg·kg−1·h−1).
Electronic charting and DoCare Clinic electronic anesthesia
recording system data were utilized during this trial. All patients
received an explanation about the operative procedure, Ramsay
sedation score (RSS), and pain score prior to the surgery. The
burr-hole surgery for CSDH was performed by a neurosurgeon
with ≥5 years of residency experience.
Anesthesia Management
No premedication was administered before surgery. Prior
to starting the surgery, ASA standard monitoring five-lead
electrocardiography, non-invasive arterial blood pressure,
peripheral pulse-oximetry (SpO2), respiratory rate (RR), and
temperature were continuously monitored using an automated
system (Philips IntelliVue MP50). Oxygen supplementation
at 3 L·min−1 was achieved through an oxygen mask; then, an
18-gauge intravenous catheter was placed in a peripheral vein
under local infiltration anesthesia. A forced-air warming device
(EQUATOR Convective Warmer, EQ-5000) was used during the
surgery to maintain normothermia.
Patients in the D1 and D2 groups received an initial loading
dose of 0.5µg·kg−1 and 1µg·kg−1 DEX, respectively, over 10
min followed by a maintenance infusion of 0.2–0.7µg·kg−1·h−1
to achieve adequate sedation. Patients in group S received
an initial loading dose of 0.3µg·kg−1 sufentanil over 10min
followed by a maintenance infusion of 0.1–0.3µg·kg−1·h−1
to achieve adequate sedation. The target RSS of the three
groups was 3 (patient exhibits response to commands). A
rescue bolus of midazolam 0.02mg·kg−1 was repeated every 5
min to a maximum dose of 2.5mg if RSS > 3 or movement
was noted during the procedure, while fentanyl 1 µg·kg−1
was repeated every 5 min to a maximum dose of 0.2mg if
the pain score (visual analog scale, VAS) >4. If the patient
did not reach the ideal status after the maximum dose of
midazolam and fentanyl was reached, propofol or GA was
administered. Once patients showed the ideal state of sedation,
the scalp was infiltrated with 5 mL of a local anesthetic solution
containing 2.5 mL of 0.5% hydrochloride ropivacaine and
2.5mL of 2% lidocaine with adrenaline at each burr hole site.
DEX and sufentanil infusion were stopped when the drainage
tube was fixed. All patients received 5mg of tropisetron and
were transferred to the post-anesthesia care unit (PACU) after
surgery.
On arrival at the PACU, vital signs (HR, non-invasive blood
pressure, RR, SpO2, temperature), RSS, and VAS were monitored
every 5 min for the first 20 min, then every 10 min for the
rest of the time until the patients were discharged to the wards
(Aldrete Score ≥ 9) (Mason et al., 2013). Surgeon satisfaction
was assessed as follows 24 h after burr-hole surgery: 1, extremely
dissatisfied; 2, not satisfied but able to manage; 3, satisfied; 4,
extremely satisfied); patients were visited to assess satisfaction on
a 7-point Likert verbal rating scale (Bagchi et al., 2014). Fentanyl,
1µg·kg−1, was given repeated every 5 min to a maximum dose of
0.2mg if VAS > 4; however, in patients with a poor response to
fentanyl or in the event of an obvious fentanyl-associated adverse
effect, 30mg of ketorolac was administered.
During the surgery, bradycardia and tachycardia were defined
as HR < 45 bpm decrease or >120 bpm increase from baseline
and treated with intravenous atropine, 0.2 mg, or esmolol,
0.4mg·kg−1, respectively. Hypertension and hypotension were
defined as a >20% increase or decrease from baseline and
treated using urapidil (10–15 mg) or phenylephrine (20–80µg),
respectively. All patients were closely continuously monitored
with the aid of five-lead electrocardiography and non-invasive
arterial blood pressure, SpO2, and RR readings using an
automated system (Philips IntelliVue MP50) for 48 h after
surgery.
Data Collection
The intraoperative hemodynamic data (HR, non-invasive blood
pressure, RR, SpO2, temperature) were obtained from a Philips
IntelliVue monitor at the following time points: arrival at
the operating room (T1); after bolus administration of drug
(T2); before administration of local anesthetic (T3); before skin
incision (T4); at 5 min (T5) and 10min (T6) after skin incision;
and at arrival (T7), 5min (T8), and 10min (T9) at the PACU.
Anesthesia onset time (from the initiation of anesthesia induction
to the onset of the surgical procedure), recovery time (from
stopping the DEX or sufentanil infusion to achieve RSS= 2), total
number of intraoperative patient movements, amount of rescue
midazolam or fentanyl, time to first dose of rescue midazolam or
fentanyl, percentage of patients converted to alternative sedative
or anesthetic therapy, adverse events, and patient and surgeon
satisfaction scores were recorded.
Statistical Analysis
The Kolmogorov–Smirnov test was used to assess the
distribution of variables. Homogeneity of variance was
determined using Levene’s tests. Quantitative data were
expressed as mean and standard deviation or median and
inter-quartile range (IQR). Inter-group comparisons were
performed using repeated-measures analysis of variance
(ANOVA). The Bonferroni’s correction was applied for post-hoc
multiple comparisons. The non-parametric Kruskal–Wallis
test was used for variables that were not normally distributed.
Categorical data were expressed as frequency and percentage
and analyzed using chi-squared tests or Fisher’s exact tests
when appropriate. Probability (P) values <0.05 were considered
statistically significant. Statistical analysis was performed
with SPSS for Windows Version 18.0 (SPSS Inc. Chicago,
IL, USA).
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RESULTS
Baseline Characteristics
Figure 1 shows the CONSORT diagram of patient recruitment.
Initially, 1832 patients who underwent burr-Hole surgery for
CSDH were screened between January 2014 and December
2015. Of these, 1617 patients were excluded for not meeting
the inclusion criteria: 1023 patients required emergency surgery;
156 patients did not fall into the specified age range of 45–65
years; the ASA grade of 124 patients was more than III; 149
patients had cardiovascular and neuropsychiatric diseases; 23
patients had a long history of addiction to alcohol, opioids,
and sedative–hypnotic drugs; the operation time of 15 patients
was shorter than 30 min; and 127 patients were excluded after
surgery due to incomplete clinical data. Finally, 215 patients
were included in the primary analysis. Demographic and baseline
clinical parameters were not significantly different among the
three groups (P > 0.05, Table 1).
Intraoperative Variables
Baseline vital signs were not statistically different among the three
groups (P > 0.05, Figure 2). Compared with S group, both D1
and D2 groups showed significantly decreased HR and MAP at
T2, T3, T4, T7, T8, and T9 (P < 0.05, Figure 2). The lowest levels
of HR and MAP among the three groups were recorded at T2.
Upon intergroup comparison, we found that anesthesia onset
time was significantly shorter in group D2 (17.36 ± 4.23 vs.
13.42 ± 2.12 vs. 15.98 ± 4.58min, respectively, for D1, D2, S;
P < 0.001, Table 2), while durations of anesthesia and surgery
and hematoma volume were not statistically different among
the three groups (P > 0.05, Table 2). More patients in groups
D1 and S required rescue midazolam to achieve RSS = 3
than in group D2 (74.63 vs. 42.67 vs. 71.23%, respectively, for
D1, D2, S; P < 0.001, Figure 3A). However, the total dose of
rescue midazolam was significantly higher in group D1 group
than that in groups S and D2 (2.8 ± 0.3 vs. 1.9 ± 0.3 vs.
2.0± 0.4mg, respectively, for D1, D2, S; P < 0.001, Figure 3A).
The time to first dose of rescue midazolam was significantly
longer in group D2 than in groups D1 and S (17.32 ± 4.47 vs.
23.56± 5.36 vs. 16.55 ± 4.91min, respectively, for D1, D2, S;
P < 0.001, Table 2). Significantly fewer patients in groups S and
D2 required rescue fentanyl to relieve pain than in group D1
(62.69 vs. 21.33 vs. 27.40%, respectively, for D1, D2, S; P < 0.001,
Figure 3B). Additionally, the total dose of rescue fentanyl in
group D1 was significantly higher than that of groups S and D2
(212.5± 43.6 vs. 107.2 ± 35.9 vs. 98.6 ± 32.2µg, respectively,
FIGURE 1 | Patient enrolment flow diagram.
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TABLE 1 | Demographic and baseline clinical parameters in the three groups.
Variable Group D1 (n = 67) Group D2 (n = 75) Group S (n = 73) P-values
Age (y) 57.53 ± 9.33 59.02 ± 8.92 55.69 ± 7.92 0.070
Body weight (kg) 72.39 ± 8.43 69.83 ± 9.34 71.98 ± 7.20 0.144
Sex (male/female) 42/25 43/32 50/23 0.380
BMI (kg·m−2 ) 23.39 ± 3.12 24.02 ± 2.92 23.87 ± 2.78 0.419
ASA (I/II/III) 18/40/9 15/48/12 15/51/7 0.623
Preoperative GCS 14.78 ± 1.09 14.88 ± 0.92 14.82 ± 1.03 0.838
Hematoma volume (mL) 52.19 ± 12.29 56.29 ± 14.82 52.95 ± 15.37 0.187
Duration of anesthesia (min) 72.23 ± 14.24 78.29 ± 17.74 75.89 ± 18.24 0.104
Duration of surgery (min) 47.24 ± 9.83 51.29 ± 11.20 48.93 ± 11.06 0.080
Comorbidity, n (%) 0.991
Hypertension 45 (67.16%) 48 (64.00%) 42 (57.53%)
Arrhythmia 8 (11.94%) 12 (16.00%) 11 (15.07%)
Diabetes mellitus 9 (13.43%) 11 (14.67%) 8 (10.96%)
COPD/asthma 3 (4.48%) 4 (5.33%) 2 (2.74%)
Anemia 13 (19.40%) 16 (21.33%) 10 (13.70%)
Variables are presented as mean ± SD or number of patients n (%). BMI, body mass index; ASA, American Society of Anesthesiology; GCS, Glasgow Coma Scale; COPD, chronic
obstructive pulmonary disease.
for D1, D2, S; P < 0.001, Figure 3B). However, the time to first
dose of rescue fentanyl was not statistically different among the
three groups (18.47 ± 3.74 vs. 18.56 ± 2.92 vs. 18.24± 3.65
min, respectively, for D1, D2, S; P = 0.845, Table 2). Total
cumulative dose of DEX was higher in group D2 (65.39 ± 18.53
vs. 92.15 ± 23.27µg, respectively, for D1 and D2; P < 0.001,
Table 2).
Total number of patient movements during the burr-hole
surgery was higher in groups D1 and S (47.76 vs. 20.00
vs. 47.95%, respectively, for D1, D2, S; P = 0.000; Table 2).
Although most of the patient movements could be controlled
with reassurance, DEX or sufentanil infusion adjustment, and
rescue drugs (midazolam or fentanyl), four patients from the D1
group and five from the S group still converted to an alternative
sedative (propofol), while no patient required GA to complete the
burr-hole surgery (Table 2).
Postoperative Variables
The time to recovery for discharge from the PACU (i.e., time to
Aldrete score ≥9) was significantly shorter in group D2 than in
groups S and D1 (16.24 ± 4.15 vs. 12.48 ± 3.29 vs. 15.91± 3.66
min, respectively, for D1, D2, S; P= 0.000, Table 3). Results from
the patient and surgeon satisfaction scores showed significant
differences favoring the D2 group compared with D1 and S
groups (P < 0.05, Table 3).
More patients in groups D1 and S than group D2 required
higher doses of urapidil (41.79 vs. 20.00 vs. 34.25%, respectively,
for D1, D2, S; P = 0.017, Table 4) and esmolol (32.84 vs. 16.00
vs. 31.51%, respectively, for D1, D2, S; P = 0.038, Table 4). The
intraoperative dose of phenylephrine (11.94 vs. 12.00 vs. 13.70%,
respectively, for D1, D2, S; P= 0.950, Table 4) and atropine (8.96
vs. 9.33 vs. 6.85%, respectively, for D1, D2, S; P = 0.824, Table 4)
were comparable among the three groups during the surgery and
in PACU.
The main adverse events are shown in Table 5. Patients
in group D2 showed lower levels of the overall incidence of
tachycardia (40.30 vs. 20.00 vs. 34.25% 25/73, respectively, D1,
D2, S; P = 0.008, Table 5) and hypertension (44.78 vs. 22.67 vs.
36.99%, respectively, for D1, D2, S; P = 0.013, Table 5). The
percentage of bradycardia, hypotension, nausea, and vomiting
were comparable among the three groups during the surgery and
in PACU (P > 0.05, Table 5). Six patients experienced respiratory
depression (defined as a respiratory rate < 8 times·min−1 or an
oxygen saturation < 90%) in group S.
DISCUSSION
Compared with sufentanil, DEX infusion at 1.0µg·kg−1 could
decrease the number of intraoperative patient movements, which
may be the primary reason for better patient and surgeon
satisfaction scores found in the D2 group. In this study, we also
found that the time to recovery from the PACU (i.e., time to
Aldrete score ≥9) was significantly shorter in group D2 than
in groups S and D1, likely because fewer patients in this group
required rescue drugs. Four patients from groupD1 and five from
group S needed to convert to alternative sedation with propofol,
although no patient required GA to complete the burr-hole
surgery. Hypotension and bradycardia were the most common
adverse events reported previously during the DEX infusion
period; however, we did not find any significant differences
among the three groups, and the few side effects seen were only
mild or moderate in severity and responded well to intervention.
Patients in group D2 also showed lower levels of tachycardia
and hypertension. An important finding of our study was that
a higher incidence of clinically significant respiratory depression
was observed in the sufentanil group than in both DEX groups.
Monitored anesthesia care has been widely used in many
clinical fields such as gastrointestinal endoscopy, septoplasty,
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FIGURE 2 | Hemodynamics monitoring across the three groups. (A)
Comparison of heart rates (HR) (beats/min) among the three groups at different
time points. (B) Comparison of mean arterial pressure (MAP) (mmHg) in the
three groups at different time points. Baseline vital signs were not statistically
difference among the three groups (P > 0.05). Compared with S group, both
HR and MAP in the D1 and D2 groups were significantly decreased at T2 (after
bolus administration of drug), T3 (before local anesthetic), T4 (before skin
incision), T7 (arrival at the PACU), T8 (5min after arrival at the PACU), and T9
(10 min after arrival at the PACU) (P < 0.05). The lowest levels of HR and MAP
among the three groups both occurred at T2. *P < 0.05 vs. group D2.
thyroplasty, interventional or radiological procedures, cataract
surgery, and awake bronchoscopy intubation (Bekker and
Sturaitis, 2005; Busick et al., 2008; Goksu et al., 2008; Dogan
et al., 2010; Parikh et al., 2013; Mondal et al., 2015). It can
provide suitable intraoperative conditions for both patients
and surgeons alike while avoiding the adverse reactions of
GA, e.g., hemodynamic instability and prolonged emergence.
Furthermore, the related hospitalization time and cost of medical
expenses are both decreased compared to surgery under GA.
The most commonly used drugs in MAC are midazolam;
propofol; and opioids such as fentanyl, alfentanil, remifentanil,
and sufentanil. Combining opioids with midazolam or propofol
was the typical solution for patients with MAC in the past;
however, increased side effects, especially cardio-respiratory
depression, were being reported (Bhananker et al., 2006; Nonaka
et al., 2015). Dexmedetomidine, a highly selective agonist of
the α2 adrenergic receptor, acts as a sedative and anxiolytic
agent through activation of the α2-adrenoreceptors located in the
central nervous system. Unlike benzodiazepines and propofol,
FIGURE 3 | (A) Percentage of patients who required rescue midazolam, and
mean midazolam dosage used during the study. (B) Percentage of patients
who did not require rescue fentanyl, and mean fentanyl dosage used in
patients requiring rescue fentanyl during the study. *P < 0.05 vs. group D2,
∧P < 0.05 vs. group S.
the sedation pathway of DEX does not depend on activation
of the α-aminobutyric acid system (Bekker and Sturaitis, 2005).
Besides, both spinal and supraspinal α2-adrenoreceptors may
contribute to the analgesic-sparing and sympatholytic effects of
DEX (Patel et al., 2010).
Intraoperative patient movement is one of the most common
causes of complications during surgery, which is often because
of inadequate sedation levels and analgesia. In this study, the
incidence of total patient movements was least in the D2
groups and comparable in groups D1 and S. Our results are
consistent with a previous study by Bekker et al. had reported.
(Bekker et al., 2004) However, Muller et al. reported that
DEX alone was not effective to provide sufficient sedation to
complete the endoscopic retrograde cholangiopancreatography
(ERCP). They also showed that patients in the DEX group
were associated with greater hemodynamic instability and longer
recovery time (Muller et al., 2008). Similarly, Tosun et al.
found that among pediatric patients who underwent cardiac
catheterization, sedation with DEX-ketamine was associated with
insufficient sedation and longer recovery time than that with
propofol-ketamine (Tosun et al., 2006). Recently, Koruk et al.
stated that both DEX and ketamine in combination with propofol
could be well tolerated in a small prospective randomized study
of pediatric patients who underwent transcatheter atrial septal
defect closure. However, the DEX-propofol group was associated
with greater hemodynamic stability and shorter recovery time
(Koruk et al., 2010). The inconsistent results among these studies
may be attributed to different types of surgery, ways of anesthesia,
or combination of drugs. In our study, the scalp was infiltrated
with 5 mL of a local anesthetic solution containing 2.5mL of
0.5% hydrochloride ropivacaine and 2.5 mL of 2% lidocaine with
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TABLE 2 | Comparison of intraoperative variables in the three groups.
Variable Group D1 (n = 67) Group D2 (n = 75) Group S (n = 73) P-values
Hematoma volume (mL) 52.19 ± 12.29 56.29 ± 14.82 50.95 ± 15.37 0.061
Duration of anesthesia (min) 72.23 ± 14.24 78.29 ± 17.74 75.89 ± 18.24 0.104
Duration of surgery (min) 47.24 ± 9.83 51.29 ± 11.20 48.93 ± 11.06 0.080
Anesthesia onset time (min) 17.36 ± 4.23 13.42 ± 2.12*∧ 15.98 ± 4.58* 0.000
Time to first dose of rescue midazolam (min) 17.32 ± 4.47 23.56 ± 5.36*∧ 16.55 ± 4.91 0.000
Time to first dose of rescue fentanyl (min) 18.47 ± 3.74 18.56 ± 2.92 18.24 ± 3.65 0.845
Total cumulative dose of dexmedetomidine (µg) 65.39 ± 18.53 92.15 ± 23.27* 0*∧ 0.000
Total patient movements, n (%) 32 (47.76%) 15 (20.00%)*∧ 35 (47.95%) 0.000
Converted to alternative sedative, n (%) 4 (5.97%) 0 (0.00%)*∧ 5 (6.85%) 0.006
Variables presented as mean ± SD or number of patients n (%). *P < 0.05 vs. group D1, ∧P < 0.05 vs. group S.
TABLE 3 | Comparison of postoperative variables in the three groups.
Variable Group D1 (n = 67) Group D2 (n = 75) Group S (n = 73) P-values
Recovery time (min) 16.24 ± 4.15 12.48 ± 3.29*∧ 15.91 ± 3.66 0.000
Patient satisfaction score 6.00 (5.25–7.00) 6.75 (5.75–7.00)*∧ 6.25 (5.25–6.75) 0.035
Surgeon satisfaction score 1.75 (1.00–2.75) 3.25 (2.75–4.00)*∧ 2.00 (1.25–3.00) 0.012
Variables presented as mean ± SD or median (interquartile range). *P < 0.05 vs. group D1, ∧P < 0.05 vs. group S.
TABLE 4 | Rescue drugs used in the three groups during surgery and in
PACU.
Variable Group D1
(n = 67)
Group D2
(n = 75)
Group S
(n = 73)
P-values
Urapidil 28 (41.79%) 15 (20.00%)*∧ 25 (34.25%) 0.017
Esmolol 22 (32.84%) 12 (16.00%)*∧ 23 (31.51%) 0.038
Phenylephrine 8 (11.94%) 9 (12.00%) 10 (13.70%) 0.950
Atropine 6 (8.96%) 7 (9.33%) 5 (6.85%) 0.824
Variables presented as number of patients n (%). *P < 0.05 vs. group D1, ∧P < 0.05 vs.
group S.
adrenaline at each burr hole site to reduce the dosage of opioids
and alleviate patient discomfort. Therefore, the requirement
for rescue drugs by the three groups in our study was less
than that previously reported (Xu et al., 2014; Bishnoi et al.,
2016; Surve et al., 2016). Although most patient movements
could be controlled with reassurance, DEX or sufentanil infusion
adjustment, or rescue drugs, nine patients still required to
convert to alternative sedation with propofol, likely owing to
the different mechanisms of DEX, sufentanil, midazolam, and
propofol sedation (Payen et al., 2007; Lebherz-Eichinger et al.,
2016).
In our study, the patient satisfaction score was higher in group
D2 than in groups D1 and S. Patient satisfaction is a direct
measure of the anesthetic care quality during surgery. A similar
result was reported by Alhashemi, who attributed this finding to
the analgesic property of DEX (Alhashemi, 2006). At the same
time, we recorded the surgeon satisfaction score, which favored
group D2. This may possibly be because of fewer intraoperative
patient movements in the D2 group (Parikh et al., 2013).
TABLE 5 | Adverse events recorded in the three groups.
Group D1
(n = 67)
Group D2
(n = 75)
Group S
(n = 73)
P-values
Tachycardia 27 (40.30%) 15 (20.00%)*∧ 25 (34.25%) 0.008
Hypertension 30 (44.78%) 17 (22.67%)*∧ 27 (36.99%) 0.013
Bradycardia 8 (11.94%) 10 (13.33%) 7 (9.59%) 0.807
Hypotension 7 (10.45%) 11 (14.67%) 9 (12.33%) 0.745
Nausea 6 (8.96%) 5 (6.67%) 7 (9.59%) 0.797
Vomiting 2 (2.99%) 1 (1.33%) 2 (2.74%) 0.744
Respiratory
depression
0 (0%) 0 (0%)*∧ 6 (8.22%)* 0.004
Variables presented as number of patients n (%). *P < 0.05 vs. group D1, ∧P < 0.05 vs.
group S.
Previous studies have reported that higher concentrations of
DEX can result in fatal adverse effects, especially by affecting
the cardiovascular system (Ebert et al., 2000; Gerlach and
Murphy, 2009). However, consistent with the report of Dere
et al. (2010), we found that more patients in groups D1 and
S required higher doses of urapidil and esmolol, while the
doses of phenylephrine and atropine were comparable among
the three groups during the surgery and in the PACU. We
believe this could be attributed to the sympathomimetic action
of DEX (Dere et al., 2010). Further, six patients in our study
experienced respiratory depression in group S, but none of them
required conversion to GA. The unique sedative property of
DEX may be the reason for the observed differences among
the three groups in our study. Unlike in previously reported
studies, the percentage of bradycardia, hypotension, nausea, and
vomiting were comparable among the three groups during the
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surgery and in the PACU; this could be because of the shorter
observation time, different types of surgery and patients, and
mode of anesthesia administration (Muttu et al., 2005; Jessen
Lundorf et al., 2016; Song et al., 2016).
We acknowledge that our study has some limitations. First,
this study was designed as a retrospective trial, while a multi-
center prospective design would have been more appropriate to
verify the feasibility of DEX alone used during burr-hole surgery
for CSDH. Second, although DEX was administered at a rate
of 1.0µg·kg−1 for 10 min, and then continued at a rate of
0.2–0.7µg·kg−1·h−1 throughout the duration of the operation,
we were unable to measure the serum concentration of DEX
owing to technical limitations and increasing hospital costs.
Third, six patients experienced respiratory depression in group
S, which may be due to the high dose of sufentanil used in this
study. Lastly, patients treated with beta-blockers and clonidine
before surgery who developed bradycardia (<50 bpm) during
the loading dose of DEX may not be suitable for this mode
of anesthetic administration. In future, more studies should be
carried out to verify the feasibility of different doses of sufentanil
alone, or in combination with other drugs, in burr-hole surgery.
In summary, our study showed that compared with sufentanil,
DEX infusion at 1µg·kg−1 for 10min (and subsequently adjusted
to 0.2–0.7µg·kg−1·h−1) alone could decrease the number of
intraoperative patient movements and amount of rescue scheme,
shorten postoperative recovery time, and provide better patient
and surgeon satisfaction. At the same time, no severe adverse
effects were recorded in either DEX group. Thus, DEX at the
studied doses is a safe and effective primary sedation alternative
to traditional opioids in patients undergoing MAC for burr-hole
surgery.
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